摘要:
The invention relates to methods of treating mesothelioma comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one therapeutic agent selected from pemetrexed, cisplatin, paclitaxel, carboplatin, and docetaxel are provided.
摘要:
Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule are provided. Methods of treating cancers comprising administering a fibroblast growth factor receptor 1 (FGFR1) extracellular domain (ECD) and/or an FGFR1 ECD fusion molecule and at least one anti-angiogenic agent are provided.
摘要:
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSFIR) in combination with one or more immune stimulating agents are provided.
摘要:
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSF1R) in combination with one or more immune stimulating agents are provided.
摘要:
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.
摘要:
Methods of treating cancer with antibodies that bind colony stimulating factor 1 receptor (CSFIR) in combination with one or more immune stimulating agents are provided.
摘要:
Methods of reducing cytokine levels and methods of treating conditions with antibodies that bind colony stimulating factor 1 receptor (CSF1R) are provided. Such methods include, but are not limited to, methods of treating inflammatory conditions, such as rheumatoid arthritis.